title: Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia.
authors.affiliation: Department of Neurology, Wolfson Medical Center, Holon, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Rapaport
authors.forename: M
authors.initials: M
authors.lastname: Sadeh
authors.forename: D
authors.initials: D
authors.lastname: Stein
authors.forename: J
authors.initials: J
authors.lastname: Levine
authors.forename: P
authors.initials: P
authors.lastname: Sirota
authors.forename: T
authors.initials: T
authors.lastname: Mosheva
authors.forename: S
authors.initials: S
authors.lastname: Stir
authors.forename: A
authors.initials: A
authors.lastname: Elitzur
authors.forename: I
authors.initials: I
authors.lastname: Reznik
authors.forename: D
authors.initials: D
authors.lastname: Geva
authors.forename: J M
authors.initials: JM
authors.lastname: Rabey
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005152:Facial Muscles / Q000187:drug effects; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D019274:Botulinum Toxins, Type A